top of page

Newsroom:

Top News

Media Inquiries

November 7, 2023

Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)

March 24, 2023

Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts

August 23, 2022

Veradermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses

Veradermics CEO Reid Waldman is selected as a Forbes 30 Under 30 for 2024

Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)

Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts

Veradermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses

In the News

In the News

Forbes

This Startup Raised $20.7 Million To Develop A Kid-Friendly Wart Treatment

Slate

Why Are We Still Killing Warts the Way We Did in the 1950s? Rethinking a pesky condition.

Business Journal

Kansas City dermatologist launches startup to address common childhood ailment

MEDIA INQUIRIES

bottom of page